Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

ar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='100060059';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.ir.oncogenex.com">www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, OGX-011/TV-1011 (custirsen). Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex's Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" p
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla ... Forecast (2011 - 2016)," analyzes the chocolate market ... major market drivers, restraints, and opportunities for the chocolate ... global chocolate market is expected to grow from $83.2 ... estimated CAGR of 2.7% from 2011 to 2016. , ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific ... and segments the bio-based advanced phase change material ... revenue. , Browse through the TOC of the ... to get an idea of the in-depth analysis ... segmentation in the Asia-Pacific bio-based advanced phase change ...
(Date:10/18/2014)... The Asian Electronic Medical Record (EMR) market report defines ... forecast of revenue. The electronic medical record market in the ... 2018, at a CAGR of 9.4% from 2013 to 2018. ... Record (EMR) market, to get an idea of the in-depth ... of the market in the same region, and is supported ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5
... XIANYANG, China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, ... Company"),a Xianyang-based developer, manufacturer and supplier of pharmaceutical,products ... and conditions,today announced that management will hold a ... 10:30 a.m. EDT on Friday, August 14, 2009. ...
... from Roman mythology when they named a unique class ... usually depicted as having two faces looking in opposite ... the tantalizing possibilities of these particles for their potential ... devices. However, realizing these applications requires precise control over ...
... SHANGHAI, Aug. 11 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... outsourcing company serving the,pharmaceutical, biotechnology, and medical device industries, ... its financial results for,second-quarter 2009. , ... 2009 Highlights, -- Net revenues totaled ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT 2Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT 3Capping a two-faced particle gives duke engineers complete control 2WuXi PharmaTech Announces Second-Quarter 2009 Results 2WuXi PharmaTech Announces Second-Quarter 2009 Results 3WuXi PharmaTech Announces Second-Quarter 2009 Results 4WuXi PharmaTech Announces Second-Quarter 2009 Results 5WuXi PharmaTech Announces Second-Quarter 2009 Results 6WuXi PharmaTech Announces Second-Quarter 2009 Results 7WuXi PharmaTech Announces Second-Quarter 2009 Results 8WuXi PharmaTech Announces Second-Quarter 2009 Results 9WuXi PharmaTech Announces Second-Quarter 2009 Results 10WuXi PharmaTech Announces Second-Quarter 2009 Results 11WuXi PharmaTech Announces Second-Quarter 2009 Results 12WuXi PharmaTech Announces Second-Quarter 2009 Results 13WuXi PharmaTech Announces Second-Quarter 2009 Results 14WuXi PharmaTech Announces Second-Quarter 2009 Results 15WuXi PharmaTech Announces Second-Quarter 2009 Results 16
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... Translational Genomics Research Institute (TGen) is presenting two key studies, ... Cancer, July 3-7 in Amsterdam. One study, presented July ... effectiveness of the most common combination chemotherapy given to patients ... today, July 7, suggests that combination drug therapy may be ...
... boy bands of Americathere,s a new group in town. ... San Diego, California, entered The Christopher Columbus Awards Competition, ... challenges middle-school students to identify a community problem and ... from the popular group the Backstreet Boys, the students ...
... Researchers at the John Theurer Cancer Center recently published a ... stem cell transplants. Scott Rowley, M.D., Chief, Blood & Marrow ... Hackensack University Medical Center contributed to the study which was ... was published in the Journal of Consulting and Clinical ...
Cached Biology News:TGen presents lung cancer studies at Amsterdam conference 2Middle-school students educate community on proper computer posture 2John Theurer Cancer Center BMT researchers highlight the importance of social support 2
... member of the caudal-related homeobox family, is ... proliferation and differentiation in intestinal epithelial cells. ... cells towards the phenotype of differentiated villus ... of the phenotype. Clone CDX2-88 reacts with ...
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
Biology Products: